3-(1H-吡洛-1-基）噻吩-2-羧酸 | 74772-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-(1H-吡洛-1-基）噻吩-2-羧酸
• 中文别名: 3-(1H-吡咯-1-基)噻吩-2-羧酸
• 英文名称: 3-(1H-pyrrol-1-yl)thiophene-2-carboxylic acid
• 英文别名: acide (pyrrolyl-1)-3 thenoique-2；3-(Pyrrol-1-yl)thiophene-2-carboxylic acid；3-pyrrol-1-yl-thiophene-2-carboxylic acid；3-pyrrol-1-ylthiophene-2-carboxylic acid
• CAS: 74772-17-1
• 化学式: C₉H₇NO₂S
• mdl: MFCD00100445
• 分子量: 193.226
• InChiKey: WSCYUZJLJQNLSQ-UHFFFAOYSA-N

物化性质

• 熔点：
  166 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	3-(1H-pyrrol-1-yl)thiophene-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	74772-17-1

Section 1 - Chemical Product MSDS Name:3-(1H-pyrrol-1-yl)thiophene-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
74772-17-1	3-(1H-Pyrrol-1-yl)thiophene-2-carboxyl	97	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 74772-17-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 174 - 176 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7NO2S
Molecular Weight: 193.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 74772-17-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1H-Pyrrol-1-yl)thiophene-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 74772-17-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 74772-17-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 74772-17-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1H-吡洛-1-基）噻吩-2-羧酸 在 sodium azide 、 TEA 、 氯甲酸乙酯 、 三氯氧磷 作用下， 以 丙酮 、 乙腈 、 苯 为溶剂， 反应 3.5h， 生成 5-[4-[3-(Trifluoromethyl)phenyl]piperazine-1-yl]-3-thia-4,8a-diaza-as-indacene
  参考文献：
  名称：

  Novel Selective and Partial Agonists of 5-HT₃ Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrrolothienopyrazines

  摘要：

  A series of piperazinopyrrolo[1,2-a]thieno[3,2-e]- and -[2,3-e]pyrazine derivatives were prepared and evaluated in order to determine the necessary requirements for high affinity on the 5-HT3 receptors and high selectivity versus other 5-HT receptor subtypes. Various substitutions on the piperazine and the thiophene ring of the pyrrolothienopyrazine moieties were systematically explored as well as replacement of the piperazine by other cyclic amines. The best compounds are in the nanomolar range of affinity for 5-HT3 receptors with high to very high selectivity (up to 10 000 for 14b). These high-affinity compounds have in common a benzyl- or allylpiperazine substituent with no substitutions on the thiophene ring. Five of these compounds (1a, 4b, 13a,b, and 14b) have been evaluated on the Von Bezold-Jarisch reflex and were characterized as partial agonists. One of them, 13a, has shown in vivo at very low dose a potent anxiolytic-like activity in the light/dark test.

  DOI：

  10.1021/jm950543x
• 作为产物：
  描述：

  3-(1-吡咯)噻吩-2羧酸甲酯 在 sodium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 3-(1H-吡洛-1-基）噻吩-2-羧酸
  参考文献：
  名称：

  血清素4受体的新型拮抗剂：吡咯烷噻吩并吡嗪类化合物的合成和生物学评估

  摘要：

  根据5-HT 4受体拮抗剂药效团的定义，一系列吡咯并[1,2- a ]噻吩并[3,2- e ]和吡咯并[1,2- a ]噻吩并[2,3- e ]设计，制备和评估吡嗪衍生物，以确定与5-HT 4受体高亲和力结合所需的性质。通过用各种N-烷基-4-哌啶基甲醇盐取代吡嗪环的氯原子来合成化合物。在结合测定中以[ 3 H] GR113808（1）作为5-HT 4受体放射性配体对它们进行了评估。亲和力值（K i（或抑制百分比）受到芳环上的取代基和侧哌啶链上的取代基的影响。三环上的甲基会显着增加亲和力，而N-丙基或N-丁基会产生具有纳摩尔亲和力的化合物。在最有效的配体中，选择34d用于进一步的药理研究并在体内进行评估。该化合物在稳定表达5-HT 4（a）受体的COS-7细胞中充当拮抗剂/弱部分激动剂，并作为一种外周镇痛药而引起了人们的极大兴趣。

  DOI：

  10.1016/j.bmc.2008.11.045

文献信息

• [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012145581A1

  公开（公告）日：2012-10-26

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• [EN] DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO[3,4-C]PYRROLES DISUBSTITUÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050198A1

  公开（公告）日：2011-04-28

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯并[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和症状的方法中有用，比如失眠。
• Pd-Catalyzed Decarboxylative Sonogashira Reaction via Decarboxylative Bromination
  作者：Quandi Jiang、Hongyi Li、Xiaofeng Zhang、Biping Xu、Weiping Su

  DOI：10.1021/acs.orglett.8b00772

  日期：2018.4.20

  The decarboxylative alkynylation of (hetero)aryl carboxylic acids with terminal alkynes has been achieved by using a Pd(PPh3)4/PCy3 catalyst. This Pd-catalyzed method exhibits good functional group tolerance for both coupling partners and enables chemical modification of complex molecules. The establishment of this decarboxylative alkynylation reaction is attributed to the discovery of a highly selective

  通过使用Pd（PPh 3）4 / PCy 3催化剂，已实现了（杂）芳基羧酸与末端炔烃的脱羧烷基化反应。这种Pd催化的方法对两个偶合伙伴均具有良好的官能团耐受性，并且能够对复杂分子进行化学修饰。该脱羧炔基反应的建立归因于发现了（杂）芳基羧酸与NBS（N-溴代琥珀酰亚胺）的高选择性脱羧溴化。
• Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue
  作者：Mira A. M. Behnam、Dominik Graf、Ralf Bartenschlager、Darius P. Zlotos、Christian D. Klein

  DOI：10.1021/acs.jmedchem.5b01441

  日期：2015.12.10

  finally fragment merging generated compounds with in vitro affinities in the low nanomolar range. The most promising derivative reached Ki values of 12 nM at the DENV-2 and 39 nM at the WNV proteases. Several of the newly discovered protease inhibitors yielded a significant reduction of dengue and West Nile virus titers in cell-based assays of virus replication, with an EC50 value of 3.4 μM at DENV-2

  登革热病毒（DENV）和西尼罗河病毒（WNV）NS2B-NS3蛋白酶是开发针对这些虫媒病毒病原体的双效治疗剂的有吸引力的靶标。我们介绍抑制剂的合成和广泛的生物学评估，该抑制剂含有4-羟基苯基甘氨酸的苄基醚作为通过铜络合物中间体合成的非天然肽类结构单元。这是一个三步优化策略，从C末端4-羟基苯基甘氨酸片段生长到苄氧基醚开始，然后是C末端和N末端优化，最后片段合并生成的化合物，该化合物具有低纳摩尔范围的体外亲和力。最有希望的导数达到K i在DENV-2中为12 nM，在WNV蛋白酶中为39 nM。在基于细胞的病毒复制试验中，一些新发现的蛋白酶抑制剂可显着降低登革热和西尼罗河病毒的滴度，其中最活跃的类似物在DENV-2处的EC 50值为3.4μM，在WNV处的EC 50值为15.5μM。
• Tricyclic oxime ethers
  申请人：Adir et Compagnie

  公开号：US05627203A1

  公开（公告）日：1997-05-06

  The present invention relates to compounds of formula (I): ##STR1## wherein A, x, y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description. The compounds are useful for treating diseases requiring a selective serotonin reuptake site and 5-HT.sub.2c or 5-HT.sub.3 ligand.

  本发明涉及以下化合物的结构（I）：##STR1## 其中A、x、y、R.sub.1、R.sub.2和R.sub.3如描述中所定义。这些化合物可用于治疗需要选择性5-羟色胺再摄取位点和5-HT.sub.2c或5-HT.sub.3配体的疾病。